Antiparkinson's Disease Drugs

Correct Answer

B — Dopamine precursor

Rationale

Levodopa is classified as a dopamine precursor. It is not itself dopamine but is converted to dopamine inside the brain by the enzyme aromatic amino acid decarboxylase. This precursor strategy is necessary because dopamine cannot cross the blood-brain barrier, while levodopa can. Dopamine agonists act by directly stimulating dopamine receptors without requiring conversion. Monoamine oxidase B inhibitors slow the breakdown of dopamine. Anticholinergic agents block muscarinic receptors to reduce cholinergic activity in the striatum.

Correct Answer

D — Anticholinergic agents

Rationale

Benztropine and trihexyphenidyl are both classified as anticholinergic agents — drugs that block muscarinic acetylcholine receptors. They are the two centrally acting anticholinergic drugs used in Parkinson's disease management. Dopamine precursors (such as levodopa) restore dopamine activity by providing a molecule that is converted to dopamine in the brain. Dopamine agonists directly stimulate dopamine receptors. Cholinesterase inhibitors block the enzyme that breaks down acetylcholine, which increases cholinergic activity — the opposite of what benztropine and trihexyphenidyl do.

Correct Answer

A — Dopamine agonists

Rationale

Pramipexole and ropinirole are both classified as dopamine agonists — drugs that directly stimulate dopamine receptors in the striatum. They belong to the non-ergot subclass of dopamine agonists, which is the preferred group in current clinical practice. Dopamine precursors (such as levodopa) must be converted to dopamine inside the brain before they are active. Anticholinergic agents block muscarinic receptors to reduce cholinergic activity. Catechol-O-methyltransferase inhibitors slow the peripheral breakdown of levodopa, extending its plasma half-life.

Correct Answer

C — Amantadine

Rationale

Amantadine is the antiparkinson drug classified as an adamantane derivative — a class of compounds characterized by a cage-like carbon ring structure. It was originally approved as an antiviral agent for influenza before its antiparkinson properties were recognized. Levodopa is a dopamine precursor derived from the amino acid tyrosine. Benztropine is an anticholinergic agent classified as a tropane derivative. Pramipexole is a non-ergot dopamine agonist. Knowing that amantadine is the adamantane-derived antiviral repurposed for Parkinson's disease is the classification fact this question tests.

Correct Answer

A — Monoamine oxidase B inhibitors

Rationale

Selegiline and rasagiline are both classified as monoamine oxidase B inhibitors — drugs that selectively block the enzyme monoamine oxidase B, which is responsible for the breakdown of dopamine in the brain. By slowing dopamine degradation, they extend the availability of dopamine in the striatum. Dopamine agonists directly stimulate dopamine receptors without requiring conversion or slowing of breakdown. Dopamine precursors, such as levodopa, are converted to dopamine inside the brain. Anticholinergic agents block muscarinic receptors to reduce striatal cholinergic activity.

Correct Answer

D — Catechol-O-methyltransferase inhibitors

Rationale

Entacapone and tolcapone are both classified as catechol-O-methyltransferase inhibitors — drugs that block the enzyme catechol-O-methyltransferase, which breaks down levodopa in peripheral tissues. By slowing this peripheral metabolism, they extend the plasma half-life of levodopa and increase the amount of each dose that reaches the brain. Dopamine agonists directly stimulate dopamine receptors. Monoamine oxidase B inhibitors slow dopamine breakdown within the brain. Anticholinergic agents reduce striatal cholinergic activity by blocking muscarinic receptors.

Correct Answer

B — Dopamine cannot cross the blood-brain barrier, while levodopa crosses via the large neutral amino acid transporter

Rationale

The blood-brain barrier excludes dopamine because it is a charged, hydrophilic molecule that cannot pass through the tight junction-protected endothelium of brain capillaries. Levodopa, by contrast, is recognized by the large neutral amino acid transporter — the same carrier that transports dietary amino acids such as phenylalanine and tyrosine — and is actively transported into the brain. Once inside, aromatic amino acid decarboxylase converts levodopa to dopamine in the striatum, replenishing the depleted neurotransmitter at the site where it is needed. Dopamine is indeed metabolized peripherally, but the primary barrier to its therapeutic use is the blood-brain barrier impermeability, not plasma half-life. Levodopa does not stimulate dopamine receptors directly — it must be converted to dopamine first, which distinguishes it from dopamine agonists such as pramipexole.

Correct Answer

C — Tremor and rigidity

Rationale

Anticholinergic drugs address tremor and rigidity most effectively because both features are driven primarily by the relative excess of acetylcholine activity that develops when dopamine input to the striatum is lost. Blocking muscarinic receptors with anticholinergic agents such as benztropine or trihexyphenidyl reduces this cholinergic excess and partially restores the dopamine-acetylcholine balance. Bradykinesia, by contrast, reflects failure of dopaminergic facilitation of movement initiation and is driven by dopamine deficiency rather than cholinergic excess — anticholinergic drugs have little benefit for this feature. Postural instability involves non-dopaminergic pathways and responds poorly to any current pharmacological intervention.

Correct Answer

A — Restoring dopaminergic tone with levodopa or dopamine agonists

Rationale

Restoring dopaminergic tone — using levodopa, dopamine agonists, monoamine oxidase B inhibitors, catechol-O-methyltransferase inhibitors, or amantadine — corrects the dopamine-acetylcholine imbalance by increasing dopamine activity in the striatum. This is the dominant pharmacological strategy in Parkinson's disease. Blocking muscarinic receptors with anticholinergic agents also corrects the same imbalance, but works from the cholinergic side rather than the dopaminergic side — this is the second strategy. Inhibiting cholinesterase would increase acetylcholine activity, deepening the imbalance rather than correcting it. Blocking glutamate receptors is the mechanism of amantadine's effect on dyskinesias, not a strategy for correcting the fundamental dopamine-acetylcholine imbalance.

Correct Answer

D — Symptoms appear after approximately 70 to 80 percent of neurons are lost

Rationale

Motor symptoms of Parkinson's disease become clinically apparent only after 70 to 80 percent of the dopamine-producing neurons in the substantia nigra pars compacta have been lost. This large reserve capacity means that neurodegeneration is already far advanced by the time a patient first presents with tremor, rigidity, or slowness of movement. The pharmacological significance of this threshold is substantial: by the time treatment begins, most of the nigrostriatal pathway has already been destroyed, and all approved drugs address only the symptomatic consequences of that loss without altering the ongoing neurodegeneration. This also explains why neuroprotective drug development — aimed at slowing neuron loss before the threshold is crossed — remains a major unmet need in Parkinson's disease.

Correct Answer

B — Bradykinesia

Rationale

Bradykinesia — slowness of movement initiation and execution — responds best to levodopa because it is most directly driven by dopamine deficiency in the nigrostriatal pathway. Restoring dopamine activity with levodopa reliably and often dramatically reduces bradykinesia, frequently to near-normal levels in the early years of treatment. Rigidity also responds well. Tremor improves in most patients but sometimes incompletely, because the relative cholinergic excess that drives tremor is not fully corrected by dopamine restoration alone — this is why anticholinergic drugs are sometimes added specifically for tremor. Postural instability responds least well to levodopa because it involves non-dopaminergic circuits that dopamine replacement cannot address.

Correct Answer

C — Muscarinic receptor blockade throughout the body causes peripheral adverse effects and central cognitive impairment that elderly patients tolerate poorly

Rationale

Anticholinergic drugs block muscarinic receptors not only in the striatum where the therapeutic effect occurs, but throughout the body. Peripheral effects include dry mouth, urinary retention, constipation, blurred vision, and tachycardia — all consequences of muscarinic blockade in salivary glands, the bladder, the gastrointestinal tract, the eye, and the heart. Central effects include confusion, memory impairment, and in severe cases delirium, because muscarinic receptors in the brain are also blocked. Elderly patients have reduced cholinergic reserve in the central nervous system and reduced ability to compensate for peripheral muscarinic blockade, making these effects both more likely and more severe. These drugs do not worsen neurodegeneration and are not ineffective for tremor in older patients per se — the issue is adverse effect burden, not pharmacological efficacy at the receptor level.

Correct Answer

A — The drug corrects the neurotransmitter imbalance in the striatum but does not slow the underlying neurodegeneration

Rationale

All currently approved pharmacological treatments for Parkinson's disease are symptomatic. They compensate for dopamine deficiency or reduce cholinergic excess, restoring the striatal neurotransmitter balance and producing functional improvement — sometimes dramatically so. However, none has been proven to slow, halt, or reverse the degeneration of substantia nigra pars compacta neurons. The underlying disease continues to progress even while the patient experiences clinical benefit. No current drug promotes neurogenesis, prevents Lewy body accumulation in a disease-modifying way, or alters the intrinsic biology of surviving neurons. This distinction between symptomatic benefit and disease modification is fundamental to counseling patients about what their medication can and cannot do.

Correct Answer

D — Dopamine agonists directly stimulate dopamine receptors in the striatum without requiring conversion to dopamine

Rationale

Dopamine agonists such as pramipexole and ropinirole bind directly to dopamine receptors — primarily D2 and D3 receptors in the striatum — and activate them without needing to be converted to any other molecule. This direct action contrasts with levodopa, which is a precursor that must be converted to dopamine by aromatic amino acid decarboxylase inside the brain before it can act. The distinction matters clinically: because dopamine agonists do not depend on surviving dopamine neurons for conversion, they can provide more continuous receptor stimulation and are associated with a lower rate of motor complications when used as initial therapy. Inhibiting the breakdown of dopamine is the mechanism of monoamine oxidase B inhibitors, not dopamine agonists. Increasing endogenous dopamine synthesis is not the mechanism of any approved antiparkinson drug class. The conversion by aromatic amino acid decarboxylase describes levodopa, not dopamine agonists.

Correct Answer

B — Restoring dopaminergic tone in the striatum with a dopamine precursor or dopamine agonist

Rationale

This patient has both bradykinesia — slowness of movement initiation, the most disabling feature of Parkinson's disease — and a resting tremor. Bradykinesia is driven primarily by dopamine deficiency in the nigrostriatal pathway and responds best to dopaminergic restoration. Restoring dopaminergic tone with levodopa or a dopamine agonist addresses both bradykinesia and tremor, because both features improve when striatal dopamine activity increases. Blocking muscarinic receptors with anticholinergic agents addresses tremor and rigidity effectively — because both are driven by the relative cholinergic excess — but has little effect on bradykinesia. For a patient whose most disabling symptom is slowness of movement, dopaminergic therapy is therefore the more complete and appropriate strategy. Inhibiting cholinesterase would increase acetylcholine activity, worsening the imbalance. Blocking N-methyl-D-aspartate receptors is the mechanism by which amantadine reduces levodopa-induced dyskinesias, not a primary strategy for newly diagnosed Parkinson's disease.

Correct Answer

A — Blockade of muscarinic receptors in the brain and bladder by the newly added drug

Rationale

This patient's new confusion and urinary retention after starting a drug for tremor points to an anticholinergic agent — most likely benztropine or trihexyphenidyl. These drugs block muscarinic receptors throughout the body. Blockade of central muscarinic receptors causes confusion, memory impairment, and delirium, which are especially severe in elderly patients whose cholinergic reserve is already reduced. Blockade of muscarinic receptors in the detrusor muscle of the bladder impairs bladder contraction, leading to urinary retention. This adverse effect profile is a predictable consequence of systemic muscarinic blockade and is precisely why anticholinergic agents are listed on the Beers Criteria as drugs to avoid in elderly patients. Excessive dopamine stimulation from combination therapy would cause hallucinations, dyskinesias, or nausea — not confusion and urinary retention. Monoamine oxidase B inhibition prolongs dopamine availability and does not block peripheral muscarinic receptors. Dopamine receptor blockade would worsen, not improve, the motor symptoms of Parkinson's disease.

Correct Answer

D — An anticholinergic agent

Rationale

Resting tremor in Parkinson's disease is driven primarily by the relative excess of striatal acetylcholine activity that results from dopamine depletion. Levodopa restores dopamine activity and often reduces tremor, but the relative cholinergic excess that drives tremor persists — some patients continue to have prominent tremor despite optimal dopaminergic therapy. Anticholinergic agents such as benztropine or trihexyphenidyl directly target this mechanism by blocking muscarinic receptors in the striatum, reducing the cholinergic excess that drives tremor. They are the drug class most specifically useful for residual tremor in younger patients. Monoamine oxidase B inhibitors and catechol-O-methyltransferase inhibitors both prolong levodopa or dopamine activity but do not specifically address the cholinergic excess responsible for tremor. Dopamine agonists further restore dopaminergic tone and may help tremor, but do not act on the cholinergic side of the imbalance that is most responsible for this feature.

Correct Answer

C — Levodopa compensates for dopamine deficiency by restoring striatal neurotransmitter balance, but the underlying neurodegeneration continues

Rationale

Levodopa and all other currently approved antiparkinson drugs are purely symptomatic treatments. They correct the functional consequence of dopamine neuron loss — the striatal dopamine-acetylcholine imbalance — producing dramatic improvement in motor function. The underlying loss of substantia nigra pars compacta neurons, however, continues at its own rate regardless of treatment. The disease will eventually progress beyond the capacity of any drug dose to compensate, which is the basis for the motor complications that emerge after years of therapy. No current drug has been proven to provide neuroprotection, stimulate neurogenesis, or prevent Lewy body formation in a way that changes the rate of neurodegeneration. This distinction between functional compensation and disease modification is fundamental to understanding what antiparkinson therapy can and cannot achieve.